Search our Database of Scientific Publications and Authors

I’m looking for a
    Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report.
    Oncol Lett 2016 Jun 19;11(6):3901-3903. Epub 2016 Apr 19.
    Department of Radiation Oncology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
    Esophageal cancer is a highly lethal malignancy of the upper gastrointestinal tract. The recurrence of the cancer indicates a poor prognosis, and even salvage therapy using multi-agent combination chemotherapy, which is considered more effective than single-agent chemotherapy, is not able to achieve a sufficient response. The present study reports the case of a 74-year-old male who presented to a local hospital with dysphagia in February 2006. Upon radiographic and pathological examination, the patient was diagnosed with squamous cell carcinoma of esophagus that was clinically staged as T3N1M1. The patient was referred to the University of Tokyo Hospital (Tokyo, Japan) for concurrent chemoradiotherapy using a radiation dose of 50.4 Gy in 28 fractions, and subsequently achieved a complete response (CR). At 8 years after the initial diagnosis and subsequent treatment, the patient presented with abdominal swollen lymph nodes that were 38 mm and 22 mm in diameter. Recurrent metastasis was diagnosed. A single-agent regimen was selected due to the patient's poor performance status. This consisted of 2 cycles of oral S-1 administration twice a day for 2 consecutive weeks, followed by 2 weeks of rest (80 mg/day for 14 days/cycle). A CR was achieved following the use of S-1 administration as salvage therapy. The patient exhibited no signs of recurrence subsequent to 9 months of follow-up. Overall, the present study reports that S-1 administration shows marked effectiveness in the treatment of huge recurrent lesions. S-1 is considered as a good treatment option in patients with poor a performance status who require salvage therapy.

    Similar Publications

    [A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
    Gan To Kagaku Ryoho 2011 Nov;38(12):2397-400
    Division of Digestive Surgery, Dept. of Surgery, Kyoto Prefectural University of Medicine.
    Patients with T4 esophageal cancer generally have poor prognosis. Of these patients, prognosis of non-responder to chemoradiothrapy (CRT) is extremely poor. We report a case of residual lymph node metastasis following definitive CRT, which showed a good response to outpatient clinic-based chemotherapy consisting of docetaxel (DOC) followed by S-1 in a patient with T4 esophageal cancer. Read More
    [Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report].
    Gan To Kagaku Ryoho 2010 Nov;37(12):2382-4
    Dept. of Gastroenterological Surgery, Kansai Rosai Hospital.
    We present a case of advanced esophageal cancer with multiple lymph node metastases successfully treated by combination therapy of docetaxel, cisplatin and 5-FU (DCF) followed by salvage lymphadenectomy. The patient was a 60-year-old female with the diagnosis of squamous cell carcinoma of the middle thoracic esophagus. The clinical stage diagnosis was cT2N4M0, cStage IVa. Read More
    Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer.
    Dis Esophagus 2014 Jan 26;27(1):42-9. Epub 2013 Feb 26.
    Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
    Local failure after definitive chemoradiotherapy (CRT) for stage IB, II, and III esophageal cancer is one of the causes of poor outcome. Endoscopic mucosal resection (EMR) is an effective treatment for superficial esophageal cancer. However, its feasibility as a salvage treatment for local recurrent or residual tumors after definitive CRT for stage IB, II, and III esophageal cancer remains unclear. Read More